FDA expands Bravecto Quantum label for two more tick species

Merck Animal Health said the FDA has approved an expanded label for Bravecto Quantum, its fluralaner extended-release injectable suspension for dogs, adding treatment and control of Asian longhorned tick and Gulf Coast tick infestations for 12 months after a single veterinarian-administered injection. The product was originally approved on July 10, 2025, as the first FDA-approved flea and tick treatment for dogs with 8- to 12-month duration, depending on tick species. With this update, Bravecto Quantum’s U.S. label now includes 12-month protection against Asian longhorned ticks, Gulf Coast ticks, black-legged ticks, American dog ticks, and brown dog ticks, while lone star tick coverage remains limited to 8 months. (merck-animal-health.com)

Why it matters: For veterinary professionals, the label expansion broadens the product’s relevance in regions where these ticks are emerging or already established. Asian longhorned ticks are an invasive species of growing concern for animal health and agriculture, and Gulf Coast ticks carry veterinary importance as vectors associated with canine hepatozoonosis and other diseases. The update may make Bravecto Quantum a more practical option for clinics looking to improve adherence through in-clinic administration, but species-specific counseling still matters because dosing intervals differ for lone star tick exposure. (aphis.usda.gov)

What to watch: Watch for how Merck positions the expanded label in practice, and whether clinics emphasize tick-species risk assessments as part of choosing 8-month versus 12-month retreatment intervals. (fda.gov)